Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 12/20 | 0.37 |
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | NRP1 | O14786 | 2/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15468396 | 0.92 | DPP7 (0.36) | DPP8DPP9DPP7DPP4F2 | |
| SCHEMBL24322781 | 0.86 | DPP8 (0.44) | DPP8DPP9DPP7DPP4ARG1 | |
| SCHEMBL10730573 | 0.86 | DPP8 (0.44) | DPP8DPP9DPP7DPP4ARG1 | |
| SCHEMBL24324302 | 0.83 | DPP7 (0.38) | DPP8DPP9DPP7DPP4ARG1 | |
| SCHEMBL24322721 | 0.83 | GAA (0.47) | DPP8DPP9DPP7DPP4ARG1 | |
| SCHEMBL11534938 | 0.83 | GAA (0.47) | DPP8DPP9DPP7DPP4ARG1 | |
| SCHEMBL27296297 | 0.83 | ARG1 (0.35) | DPP8DPP9DPP7DPP4ARG1 | |
| Arginine SCHEMBL27748019 | 0.81 | OTC (0.49) | ARG1 | |
| Arginine SCHEMBL18788608 | 0.81 | OTC (0.49) | ARG1 | |
| SCHEMBL15941314 | 0.80 | NPY4R (0.33) | DPP8DPP9DPP7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | DPP8 296/4885DPP9 138/4885DPP7 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.